EGFR and cancer: EGFR activation is primarily involved in the malignant progression and chemotherapeutic resistance of cancer through the epithelial-mesenchymal transition (EMT), enhancing the mesenchymal fate by activation of the mitogen-activated protein kinase/ERK kinase (MEK)/ERK and Janus kinase (JAK)2/STAT3 pathways [33,34].